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Background: The purpose of this study was to evaluate the incidence of contrast-
induced nephropathy (CIN), and the effect of intravenous albumin for prophylaxis
of CIN in patients with liver cirrhosis (LC) and chronic kidney disease (CKD).
Methods: We conducted a retrospective study of 81 subjects with LC and CKD
(estimated glomerular ﬁltration rate (eGFR)o60 mL/min/1.73 m2) who underwent
contrast-enhanced computed tomography (CT). Patients received either isotonic
sodium bicarbonate solution (3 mL/kg for 1 h before CT and 1 mL/kg/h for 6 h after
CT) or albumin (20% albumin, 25 mL for 1 h before CT and 75 mL for 6 h after CT).
CIN was deﬁned as an increase of Z25% or Z0.5 mg/dL in serum creatinine level.
Results: Overall, CIN developed in three patients (3.7%). Of the 81 subjects, 43
received sodium bicarbonate solution and 38 received albumin. Both groups were
comparable with regard to age, sex, diabetes mellitus, and baseline eGFR. The
albumin group showed a signiﬁcantly poorer liver function proﬁle. CIN incidence
did not differ signiﬁcantly between the groups: it occurred in one (2.3%) of the 43
subjects receiving sodium bicarbonate and two (5.3%) of the 38 subjects receiving
albumin (P¼0.6). However, the albumin group showed a signiﬁcantly smaller
increase in body weight (P¼0.03).
Conclusion: The incidence of CIN in patients with LC and CKD undergoing contrast-
enhanced CT after preventive measures was relatively low. The incidence of CIN was
not signiﬁcantly different between sodium bicarbonate and albumin groups.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Renal failure is a common and serious complication in patients
with liver cirrhosis (LC), and is a predictor of poor outcome [1–3].rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
logy, Samsung Medical
edicine, 50 Irwon-dong,
m (DJ Kim).Patients with LC are susceptible to renal failure primarily because
of disturbances in circulatory function (splanchnic vasodilation,
intravascular volume depletion, and altered renal hemody-
namics). Gastrointestinal bleeding, paracentesis, and administra-
tion of nephrotoxic drugs such as aminoglycosides and contrast
agents also cause renal insufﬁciency [4,5].
Contrast-induced nephropathy (CIN), deﬁned as a rapid
deterioration in renal function after administration of contrast
medium without other speciﬁc causes, is a common cause ofublished by Elsevier. This is an open access article under the CC BY-NC-
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(CKD) is known to be the most important risk factor for CIN;
diabetes, heart failure, and injection of a large amount of
contrast agent are also considered risk factors. Although it has
been suggested that LC may be a risk factor for CIN, this has
not yet been conﬁrmed. LC patients with renal insufﬁciency
are likely to be more vulnerable to CIN, but there has been no
research on this topic in such patients.
Although the optimal therapy for prevention of CIN
remains uncertain, it is widely recommended that intrave-
nous isotonic ﬂuid and oral N-acetylcysteine be administered
to high-risk patients before and after they receive a radio-
contrast agent. However, in patients with LC, isotonic ﬂuid
may aggravate ascites and volume overload. Albumin infu-
sions have been used in patients with LC for volume expan-
sion after paracentesis or in hepatorenal syndrome. Unlike
crystalloid ﬂuid, albumin increases only the intravascular
volume and also has antioxidant effects, so is considered to
prevent CIN. However, to the best of our knowledge, no
research on the effect of intravenous albumin on prevention
of CIN in patients with LC has been reported.
The aim of the present study was to examine the incidence of
CIN and the effect of intravenous albumin compared with
isotonic sodium bicarbonate solution for the prevention of CIN
in patients with LC and CKD undergoing contrast-enhanced
computed tomography (CT) in an outpatient setting.
Methods
Setting
This study was a retrospective observational study per-
formed at a single center. Samsung Medical Center is a tertiary
referral hospital in Seoul, Korea and over 40,000 contrast-
enhanced CT scans are performed annually in its clinics. The
ﬁve-bed short stay unit was established in October 2009 to
provide short-stay treatment to prevent the occurrence of CIN in
patients with CKD after contrast-enhanced CT.
The contrast agents used for CT scans are low-osmolality
contrast agents. For CT scans other than coronary CT angio-
graphy, one of the following four contrast agents is randomly
given to patients in speciﬁed amounts, depending on the
area to be scanned: iobitridol (Xenetix 300; 300 mg iodine/
mL, 695 mOsm/kg; Guerbet, Aulnay S. Bois, France), iomeprol
(Iomeron 300; 300 mg iodine/mL, 520 mOsm/kg; Ilsung
Pharmaceuticals, Seoul, Korea), iohexol (Omnipaque 300;
300 mg iodine/mL, 672 mOsm/kg; GE Healthcare, Little Chal-
font, UK), iopromide (Ultravist 300; 300 mg iodine/mL,
586 mOsm/kg; Bayer Healthcare, Berlin, Germany). For cor-
onary CT angiography, iomeprol (Iomeron 350; 350 mg io-
dine/mL, 620 mOsm/kg; Ilsung Pharmaceuticals) is used and
one of the subjects of this study received this agent.
Standard CIN prophylaxis protocol
The standard CIN prophylaxis protocol in our institution
is as follows. Patients receive an intravenous injection of
3 mL/kg/h and of isotonic sodium bicarbonate ﬂuid for 1 h
before the CT scan and 1 mL/kg/h for 6 h after the CT scan. The
patients take N-acetylcysteine 1200 mg orally twice daily on
the day before and on the day of CT. Serum creatinine is
measured when the patient comes to the outpatient clinic 2–5
days after leaving the hospital.Patients with LC who consent receive an intravenous
injection of 100 mL of 20% albumin before and after the CT
scan. They are injected with 25 mL for 1 h before the CT scan
and 75 mL for 6 h after the CT scan (albumin group) and take
N-acetylcysteine according to the same protocol as for the
group receiving isotonic sodium bicarbonate. If patients do
not agree to the infusion of albumin, isotonic sodium bicar-
bonate is injected (bicarbonate group).
Patients
The study subjects were patients with LC who stayed in the
short-stay unit of the hospital between October 2009 and
February 2011 and who underwent a CT scan after the CIN
prophylaxis protocol. We included those patients whose
estimated glomerular ﬁltration rate (eGFR) was below
60 mL/min/1.73 m2 on the day of their CT scan. The diagnosis
of LC was made on the basis of the usual clinical, laboratory,
and radiologic ﬁndings. The study was approved by the
Institutional Review Board of the hospital.
Measures
The medical records and electronic data for patients included
in the study were reviewed retrospectively to check clinical
characteristics such as age, sex, body weight, diabetes mellitus,
hypertension, causes of LC, existence of hepatocellular carcinoma,
and medications (diuretics, angiotensin-converting enzyme inhi-
bitor or angiotensin receptor blocker, statin). Child–Pugh classi-
ﬁcations were assessed to examine the severity of LC. Baseline
serum creatinine and total CO2 weremeasured before the CT scan
on the same day, and were measured again at outpatient clinics
2–5 days after the CT scan to assess the development of CIN. CIN
was deﬁned as an increase of Z25% or Z0.5 mg/dL in serum
creatinine level. Estimated GFR was based on the abbreviated
Modiﬁcation in Diet and Renal Disease Study equation and
calculated as follows: eGFR (mL/min/1.73 m2)¼175 (serum
creatinine)1.154 (age)0.203 (0.742, if female) [7].
Statistical analysis
Data are expressed as mean7SD. Categorical variables for
the two groups were compared using a w2 test or Fisher’s
exact test. Continuous variables were compared using an
unpaired t test if the data from both groups had a normal
distribution, but the Mann–Whitney test was applied if data
from either of the two groups did not have a normal
distribution. Two-sided P values are reported, with 0.05 as
the level of signiﬁcance. All statistical analyses were per-
formed using SPSS 12.0 (SPSS, Chicago, IL, USA).
Results
Baseline characteristics and CIN incidence
A total of 67,302 contrast-enhanced CT scans were per-
formed in our outpatient clinics from October 2009 to February
2011. Some 1111 of these were performed after implementa-
tion of preventive treatments in the short-stay unit, and 107
patients who underwent such treatment had LC. Excluding the
13 patients with eGFRZ60 mL/min/1.73 m2 on the day of the
CT scan and 13 patients who were not followed up at out-
patient clinics after their CT scan, 81 patients were included.
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are shown in Tables 1 and 2. The mean age was 65.7 years and
62 patients (76.5%) were male. Diabetes mellitus was found in
39 patients (48.1%) and hypertension in 31 patients (38.3%).
The mean baseline serum creatinine was 1.73 mg/dL and
mean eGFR was 40.5 mL/min/1.73 m2. Hepatitis B was the
most common cause of LC and hepatocellular carcinoma was
identiﬁed in 70 of 81 patients (86%).
Overall, CIN developed in three patients, representing an
incidence of 3.7% (Table 3). Patients with ascites were at
increased risk of developing CIN (P¼0.02; Table 4). In two of
the three patients with CIN, renal function improved to the
baseline serum creatinine level during their outpatientTable 1. Baseline clinical and biochemical characteristics of the study
Characteristics Total (n¼81) Sodi
Age (years) 65.778
Male 62 (76.5)
Diabetes mellitus 39 (48.1)
Hypertension 31 (38.3)
Cause of chronic kidney disease
Diabetes mellitus 31 (38.3)
Hypertension 20 (24.7)
Glomerulonephritis 15 (18.5)
Unknown 15 (18.5)
Serum creatinine (mg/dL) 1.7370.6
eGFR (mL/min/1.73 m2) 40.5710
Serum total CO2 (mEq/L) 19.573.1
Use of diuretics 25 (30.9)
Use of ACE inhibitor/ARB 27 (33.3)
Use of statins 8 (9.9)
Data are expressed as mean7SD or number (percentage).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; e
Table 2. Baseline liver function tests and cirrhosis etiology for the stu
Characteristics Total (n¼81) Sodium b
Bilirubin (mg/dL) 0.970.7
Albumin (g/dL) 3.770.6
Prothrombin time (INR) 1.270.2
Child–Pugh class (A/B/C) 59/20/2
Etiology of cirrhosis
Alcoholism 14 (17.3)
Hepatitis B 51 (63)
Hepatitis C 5 (6.2)
Primary biliary 1 (1.2)
Cryptogenic 10 (12.3)
Hepatocellular carcinoma 70 (86.4)
Ascites on CT scan 22 (27.1)
Data are expressed as mean7SD or number (percentage).
CT, computed tomography; INR, international normalized ratio.
Table 3. Contrast volumes and biochemical responses in patients rece
Characteristics Total (n¼81)
Contrast medium volume by body weight (mL/kg) 1.970.3
Change in serum creatinine (mg/dL) 0.0370.2
Change in eGFR (mL/min/1.73 m2) 0.175.1
Change in serum total CO2 (mEq/L) 2.672.5
Incidence of CIN 3 (3.7)
Change in body weight (kg) 0.370.8
Data are expressed as mean7SD or number (percentage).
CIN, contrast induced nephropathy; eGFR, estimated glomerular ﬁltration rfollow-up. The remaining patient, who had baseline eGFR of
8.9 mL/min/1.73 m2, refused further aggressive treatment
including hemodialysis because of advanced hepatocellular
carcinoma. He was discharged from the hospital and died 26
days after his CT scan (Table 5).
Effect of intravenous albumin on CIN prevention
Of the 81 study patients, 43 received sodium bicarbonate
and 38 received albumin. The clinical and laboratory char-
acteristics of the two groups are shown in Table 1. There were
no signiﬁcant differences between the groups in age, sex,
diabetes mellitus, and baseline renal function. The albuminpatients
um bicarbonate (n¼43) Albumin (n¼38) P
66.278.4 65.177.6 0.4
34 (79.1) 28 (73.7) 0.6
17 (39.5) 22 (57.9) 0.1
19 (44.2) 12 (31.6) 0.2
17 (39.5) 14 (36.8)
13 (30.2) 7 (18.4)
8 (18.6) 7 (18.4)
5 (11.6) 10 (26.3)
1.670.3 1.870.9 0.9
41.378.1 39.7711.8 0.5
19.673.1 19.573.2 0.8
9 (20.9) 16 (42.1) 0.04
18 (41.9) 9 (23.7) 0.08
1 (2.3) 7 (18.4) 0.02
GFR, estimated glomerular ﬁltration rate.
dy patients
icarbonate (n¼43) Albumin (n¼38) P
0.770.5 1.270.8 0.004
4.070.4 3.470.6 o0.001
1.170.2 1.370.2 o0.001
39/4/0 20/16/2 o0.001
9 (20.9) 5 (13.2)
26 (60.5) 25 (65.8)
3 (7.0) 2 (5.3)
1 (2.3) 0 (0.0)
4 (9.3) 6 (15.8)
33 (76.7) 37 (97.4) 0.007
6 (14.0) 16 (42.1) 0.007
iving either sodium bicarbonate or albumin
Sodium bicarbonate (n¼43) Albumin (n¼38) P
2.070.3 1.970.3 0.07
0.0170.2 0.0670.3 0.3
0.6775.1 –0.5475.1 0.3
2.972.2 2.272.7 0.2
1 (2.3) 2 (5.3) 0.6
0.570.7 0.170.9 0.03
ate.
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diuretics (P¼0.04) or statins (P¼0.02).
The albumin group had a signiﬁcantly poorer liver function
proﬁle than the sodium bicarbonate group: higher bilirubin
(0.7 mg/dL for sodium bicarbonate and 1.2 mg/dL for albu-
min; P¼0.004) and prothrombin time (international normal-
ized ratio 1.1 for sodium bicarbonate and 1.3 for albumin;
Po0.001) and lower albumin (4.0 g/dL for sodium bicarbo-
nate and 3.4 g/dL for albumin; Po0.001). In terms of the
Child–Pugh classiﬁcation, the albumin group had a signiﬁ-
cantly higher proportion of patients in the Child–Pugh class B
or C (Po0.001). Six patients (14%) in the sodium bicarbonate
group and 16 (42.1%) in the albumin group had ascites
(P¼0.007).
CIN developed in one (2.3%) of the 43 patients receiving
sodium bicarbonate and two (5.3%) of the 38 patients receiv-
ing albumin; this difference was not signiﬁcant (P¼0.6). The
albumin group showed a signiﬁcantly smaller increase in
body weight; the average weight of the group increased by
0.1 kg compared with 0.5 kg for the sodium bicarbonate
group (P¼0.03; Table 3).
None of the patients who received sodium bicarbonate or
albumin showed any complication related to ﬂuid administration.Table 5. History and clinical outcome for patients with contrast-induc
Patient Sex Age (y) Fluid DM Baseline Cr
(mg/dL)
Bas
(mL/
1 M 66 Albumin Yes 1.94
2 M 80 Albumin Yes 6.11
3 M 72 Sodium bicarbonate Yes 1.9
Cr, creatinine; DM, diabetes mellitus; eGFR, estimated glomerular ﬁltration
Table 6. Literature review of contrast-induced nephropathy in patients
Study LC patients LC patients with CKD
(CKD deﬁnition)
Najjar et al. [12] 72 2 (Cr41.5 mg/dL)
Guevara et al. [11] 31 5 (GFRo50 mL/min)
Lodhia et al. [13] 216 3 (Cr41.5 mg/dL)
n No clear deﬁnition of CIN was provided.
y CIN was deﬁned as a decrease of Z25% in creatinine clearance using the
CIN, contrast-induced nephropathy; CKD, chronic kidney disease; Cr, creat
Table 4. Clinical characteristics of patients with and without
contrast-induced nephropathy
Characteristics No CIN
(n¼78)
CIN (n¼3) P
Age (years) 65.477.9 73 (66–80) 0.1
Diabetes mellitus 36 (46.2) 3 (100) 0.1
Use of diuretics 25 (32.1) 0 (0.0) 0.5
Baseline eGFR (mL/min/1.73 m2) 0.1
Z45 to o60 29 (37.2) 0 (0.0)
Z30 to o45 39 (50.0) 2 (66.7)
o30 10 (12.8) 1 (33.3)
Ascites 19 (24.4) 3 (100) 0.02
Data are expressed as mean7SD or median (range) for nonparametric
variables, or number (percentage).
CIN, contrast induced nephropathy; eGFR, estimated glomerular ﬁltra-
tion rate.Discussion
In the present study, patients with LC and renal insufﬁ-
ciency (eGFRo60 mL/min/1.73 m2) received CIN prophylaxis
of isotonic sodium bicarbonate or albumin before and after a
CT scan; CIN occurred in 3.7%. There was no signiﬁcant
difference in CIN incidence between the sodium bicarbonate
and albumin groups, but the albumin group showed a smaller
increase in weight. Underlying renal insufﬁciency is the most
important risk factor for CIN, and CIN incidence after a CT
scan in patients with CKD can range from 2.5% to 12% [8–10].
Considering that the patients surveyed for this study had both
renal insufﬁciency and LC, the CIN incidence observed seems
to be relatively low.
LC has not been veriﬁed as a risk factor for CIN and only
three small studies on this issue have been reported (Table 6).
Guevara et al. prospectively followed the renal function of 31
patients with LC after administering a contrast agent [11]. The
glomerular ﬁltration rate was measured by 125I-iothalamate
clearance and no signiﬁcant changes in renal function were
observed. As patients with serum creatinine of 2 mg/dL or
higher were excluded, the mean baseline serum creatinine
was 0.970.02 mg/dL. Only ﬁve patients with GFRo50 mL/
min were included. In a retrospective case-control study of 72
patients with LC performed by Najjar et al., the CIN incidence
was not higher than for patients without LC [12]. Although
CIN was not clearly deﬁned in this study, CIN developed in
two (2.8%) of 72 LC patients. Two patients with CKD (serum
creatinine41.5 mg/dL) were included among the 72 patients,
and one suffered from CIN. Lodhia et al. also carried out a
retrospective study of 216 patients with LC in 2009 in which
CIN developed in 25% of patients [13]. CIN was deﬁned as a
decrease in creatinine clearance of 25% or more and patients
with baseline serum creatinine of 1.8 mg/dL or higher were
excluded. Only three patients with serum creatinine of
1.5 mg/dL or higher were included, and CIN occurred in one.
All three studies were based on a limited number of
patients, and the study by Lodhia et al. [13] had no control
group because it was a retrospective study. The three studies
were also based on hospitalized patients with LC, only a few
patients had renal insufﬁciency, and no preventive treatment
was performed before and after the CT scan.ed nephropathy
eline eGFR
min/1.73 m2)
Child–Pugh class Ascites Peak serum
Cr (mg/dL)
Outcome
34.8 B Yes 2.99 Improved
8.9 B Yes 6.73 Death
34.9 A Yes 2.39 Improved
rate.
with liver cirrhosis after contrast-enhanced computed tomography.
Baseline serum
Cr (mg/dL)
CIN incidence
in LC patients
CIN incidence in
LC patients with CKD
0.8770.06 2/72 (2.8%)* 1/2
0.970.02 (0.3–1.9) 0/31 0/5
Not reported 53/216 (25%)y 1/3
Cockcroft–Gault equation.
inine; GFR, glomerular ﬁltration rate; LC, liver cirrhosis.
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and the reported incidence ranges from 23% [5,14] to 44%
[15]. The most common causes of renal insufﬁciency are
prerenal, including infection, hypovolemia, vasoconstriction
caused by nonsteroidal anti-inﬂammatory drugs or radio-
contrast agents, and hepatorenal syndrome. In addition to
these, intrinsic renal factors such as acute tubular necrosis
and glomerulonephritis and post-renal obstruction are con-
sidered to be causes. Since the three studies described above
were based on hospitalized patients with LC, some patients
may have suffered from renal failure caused by factors other
than CIN. However, renal insufﬁciency caused by factors other
than CIN can be ruled out in our study, because participants
were outpatients. Prakash et al. reported that many patients
with renal insufﬁciency and LC could be categorized as having
CKD (63/178, 35%) [15]. Because CKD is the most important
factor that increases susceptibility to CIN and the prognosis of
LC patients who have acute renal failure is poor, it is
important to prevent CIN when a radiocontrast agent is
injected into a patient with LC and renal insufﬁciency.
Albumin is the most abundant plasma protein and is
responsible for 70% of the plasma oncotic pressure [16].
Albumin plays various roles in the human body, and its most
important role is to maintain intravascular volume and
colloid oncotic pressure. Its other physiological functions are
to bind ligands, carry various materials including hormones,
lipids, and drugs, and act as an antioxidant [17].
Indications for the infusion of albumin have not been
clearly deﬁned, and the procedure is still controversial. It
has not been demonstrated to be better than crystalloid ﬂuid
for volume expansion in acute hypovolemia [18], and has not
been shown to have beneﬁts for patients with hypoalbumi-
nemia [19]. The use of albumin infusion is recommended in
LC patients with spontaneous bacterial peritonitis, hepator-
enal syndrome, and large-volume paracentesis [20].
It has been hypothesized that the two major mechanisms
underlying the pathogenesis of CIN are renal vasoconstriction
and direct cytotoxic effects of contrast agents. Renal blood
ﬂow decreases by 30–45% within 2–4 h after injection of a
contrast agent [21,22], which could lead to a deterioration in
renal function because of medullary hypoxia. Another possi-
ble cause is the direct cytotoxic effect of oxygen free radicals
created after injection of a radiocontrast agent, which cause
renal tubular injury [23,24]. It has been shown the hydration
with isotonic ﬂuid is an effective strategy for CIN prevention,
and addition of oral N-acetylcysteine, which is expected to
have an antioxidant effect, is recommended for high-risk
patients.
If albumin is infused before and after a CT scan, it has
volume expansion and antioxidant effects and is thus
expected to help prevent the occurrence of CIN. First, its
effect on volume expansion is assessed. Although each gram
of albumin theoretically binds approximately 18 g of water, a
study of plasma volume expansion in patients injected with
50 g of albumin after surgery showed that this increased
plasma volume by approximately 500 mL (or 11 mL/g of
retained albumin), which was less than expected [25]. If a
patient weighing 60 kg is injected with isotonic sodium
bicarbonate in accordance with our protocol, the total volume
of ﬂuid injected before and after the CT scan amounts to
540 mL (180 mL before the CT scan, 360 mL after the CT scan).
Assuming that a quarter of the isotonic sodium bicarbonate
solution is accounted for by ﬂuid in the intravascular space,this equals 135 mL (45 mL before and 90 mL after the CT
scan). The total injection of albumin in this study was 20 g.
Assuming that 1 g of albumin was combined with 11 mL of
water, this amounts to 220 mL (55 mL before and 165 mL
after the CT scan). According to our study results, injection of
albumin increased expansion of the intravascular volume,
but induced a limited weight increase after ﬂuid injection.
Second, with respect to the antioxidant effects of albumin, it
has been reported that a physiological solution of human
serum albumin restricts the creation of oxygen free radicals
by polymorphonuclear leukocytes [17,26]. In a clinical
study that measured endotoxin, nitric oxide products, tumor
necrosis factor (TNF)-a, and interleukin (IL)-6 in patients
with spontaneous bacterial peritonitis and LC, a group
injected with albumin showed a signiﬁcant decrease in TNF-
a and IL-6 compared with a group without albumin injection
[27]. Patients with acute lung injury had an increased anti-
oxidant capacity after injection of albumin [28]. If albumin is
injected before and after injection of a contrast agent, it is
expected to scavenge oxygen free radicals, a major cause
of CIN.
Comparison of patients with and without CIN showed
no signiﬁcant difference in age or frequency of diabetes
mellitus, both of which are known to be major risk factors
for CIN. Although the incidence of CIN increased as the
baseline eGFR decreased [0% (0/29) for 45reGFRo60, 4.9%
(2/41) for 30reGFRo45, 9.1% (1/11) for eGFRo30], the
correlation was not signiﬁcant (P¼0.1). This may be because
our study involved a limited number of patients and CIN
cases. All patients with CIN had ascites according to CT
imaging, and thus patients with ascites had a signiﬁcantly
higher incidence of CIN (P¼0.02). The study by Lodhia et al.
showed similar results [13], which suggests that ascites can
cause intravascular volume depletion and increase the inci-
dence of CIN.
Our study has several limitations. First, it is a retrospective
study. Because of the lack of randomization and differences in
baseline characteristics between the sodium bicarbonate
and albumin groups, the effect of preventive measures
could not be clearly deﬁned. Second, since only patients
who agreed to use the short-stay unit were included in the
study, the incidence of CIN among patients who underwent a
CT scan without preventive treatment could not be assessed.
Third, CIN was deﬁned on the basis of serum creatinine,
but serum creatinine in patients with LC is an unreliable
marker of renal function [29]. Inulin clearance or 24-h
urine collection can be used for more accurate assessment
of renal function, but these methods were not feasible in this
retrospective study of outpatients who were hospitalized for a
short period. Furthermore, because the creatinine was
measured once for each patient at variable time intervals
after the CT scan, we may have missed some patients who
developed CIN.
In conclusion, in patients with LC and CKD, the incidence of
CIN after contrast-enhanced CT was relatively low after
preventive therapy with intravenous volume expansion and
oral N-acetylcysteine. The incidence of CIN after intravenous
administration of isotonic sodium bicarbonate or albumin did
not signiﬁcantly differ. However, the group administered
albumin showed a smaller increase in weight and patients
with ascites were found to be more vulnerable to CIN. Further
large randomized controlled trials are warranted to investi-
gate the preventive effect of albumin on CIN.
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